Cabometyx is already approved as a second-line treatment for HCC in people who have previously received Nexavar, along with first- and second-line approvals for RCC, with sales reaching $720 ...
The European Commission has approved Ipsen’s Cabometyx for liver cancer, in adults previously treated with Bayer’s Nexavar. The commission granted a marketing authorisation for Cabometyx ...
Cabometyx (cabozantinib) is a brand-name oral tablet prescribed for certain types of cancer in adults and some children. The cost of the drug, with and without insurance, can depend on several ...